Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Johnson and Johnson
Medtronic
McKinsey

Last Updated: August 13, 2022

Investigational Drug Information for PF-06700841


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for PF-06700841?

PF-06700841 is an investigational drug.

There have been 20 clinical trials for PF-06700841. The most recent clinical trial was a Phase 2 trial, which was initiated on December 15th 2016.

The most common disease conditions in clinical trials are Psoriasis, Alopecia Areata, and Alopecia. The leading clinical trial sponsors are Pfizer, Emma Guttman, and [disabled in preview].

There are two US patents protecting this investigational drug and fifty international patents.

Recent Clinical Trials for PF-06700841
TitleSponsorPhase
Dual JAK1/TYK2 Inhibitor for Cicatricial AlopeciaPfizerPhase 2
Dual JAK1/TYK2 Inhibitor for Cicatricial AlopeciaEmma GuttmanPhase 2
Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release FormulationsPfizerPhase 1

See all PF-06700841 clinical trials

Clinical Trial Summary for PF-06700841

Top disease conditions for PF-06700841
Top clinical trial sponsors for PF-06700841

See all PF-06700841 clinical trials

US Patents for PF-06700841

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06700841 See Plans and Pricing Aminopyrimidinyl compounds Pfizer Inc. (New York, NY) See Plans and Pricing
PF-06700841 See Plans and Pricing Aminopyrimidinyl compounds Pfizer Inc. (New York, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06700841

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06700841 Argentina AR101599 2034-08-21 See Plans and Pricing
PF-06700841 Australia AU2015304883 2034-08-21 See Plans and Pricing
PF-06700841 Brazil BR112017003054 2034-08-21 See Plans and Pricing
PF-06700841 Canada CA2900855 2034-08-21 See Plans and Pricing
PF-06700841 Chile CL2017000406 2034-08-21 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
AstraZeneca
Johnson and Johnson
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.